Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Old medications and new targeted therapies in systemic sclerosis.

Literature DB >> 25065013

Old medications and new targeted therapies in systemic sclerosis.

Vivek Nagaraja¹, Christopher P Denton², Dinesh Khanna³.

Abstract

SSc is a multiorgan disease with significant morbidity that is associated with poor health-related quality of life. Treatment of this condition is often organ based and non-curative. However, there are newer, potentially disease-modifying therapies available to treat certain aspects of the disease. This review focuses on old and new therapies in the management of SSc in clinical practice.

Entities: Disease

Keywords: Raynaud’s phenomenon; digital ulcers; immunosuppressive therapy; interstitial lung disease; pulmonary arterial hypertension; renal crisis; skin fibrosis; systemic sclerosis; treatment

Mesh：

Substances：
Antirheumatic Agents

Year: 2014 PMID： 25065013 PMCID： PMC4603276 DOI： 10.1093/rheumatology/keu285

Source DB: PubMed Journal: Rheumatology (Oxford) ISSN： 1462-0324 Impact factor: 7.580

82 in total

1. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.

Authors: J R Seibold; C P Denton; D E Furst; L Guillevin; L J Rubin; A Wells; M Matucci Cerinic; G Riemekasten; P Emery; H Chadha-Boreham; P Charef; S Roux; C M Black
Journal: Arthritis Rheum Date: 2010-07

2. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.

Authors: M Dziadzio; C P Denton; R Smith; K Howell; A Blann; E Bowers; C M Black
Journal: Arthritis Rheum Date: 1999-12

3. Adventitial stripping: a digit saving procedure in refractory Raynaud's phenomenon.

Authors: A M Yee; R N Hotchkiss; S A Paget
Journal: J Rheumatol Date: 1998-02 Impact factor: 4.666

4. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.

Authors: Janet Pope; Donna McBain; Lisa Petrlich; Sharon Watson; Louise Vanderhoek; Faye de Leon; Shannon Seney; Kelly Summers
Journal: Arthritis Rheum Date: 2011-11

5. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.

Authors: Paul J DeMarco; Michael H Weisman; James R Seibold; Daniel E Furst; Weng Kee Wong; Eric L Hurwitz; Maureen Mayes; Barbara White; Fredrick Wigley; Walter Barr; Larry Moreland; Thomas A Medsger; Virginia Steen; Richard W Martin; David Collier; Arthur Weinstein; Edward Lally; John Varga; Steven R Weiner; Brian Andrews; Micha Abeles; Philip J Clements
Journal: Arthritis Rheum Date: 2002-11

6. Long-term outcomes of scleroderma renal crisis.

Authors: V D Steen; T A Medsger
Journal: Ann Intern Med Date: 2000-10-17 Impact factor: 25.391

7. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

Authors: O Kowal-Bielecka; R Landewé; J Avouac; S Chwiesko; I Miniati; L Czirjak; P Clements; C Denton; D Farge; K Fligelstone; I Földvari; D E Furst; U Müller-Ladner; J Seibold; R M Silver; K Takehara; B Garay Toth; A Tyndall; G Valentini; F van den Hoogen; F Wigley; F Zulian; Marco Matucci-Cerinic
Journal: Ann Rheum Dis Date: 2009-01-15 Impact factor: 19.103

8. An International, Web-Based, Prospective Cohort Study to Determine Whether the Use of ACE Inhibitors prior to the Onset of Scleroderma Renal Crisis Is Associated with Worse Outcomes-Methodology and Preliminary Results.

Authors: Marie Hudson; Murray Baron; Ernest Lo; Joanna Weinfeld; Daniel E Furst; Dinesh Khanna
Journal: Int J Rheumatol Date: 2010-09-14

9. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.

Authors: C P Denton; M Engelhart; N Tvede; H Wilson; K Khan; X Shiwen; P E Carreira; F Diaz Gonzalez; C M Black; F H van den Hoogen
Journal: Ann Rheum Dis Date: 2008-09-09 Impact factor: 19.103

10. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.

Authors: Dinesh Khanna; Xiaohong Yan; Donald P Tashkin; Daniel E Furst; Robert Elashoff; Michael D Roth; Richard Silver; Charlie Strange; Marcy Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean E Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fredrick Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky; Philip J Clements
Journal: Arthritis Rheum Date: 2007-05

23 in total

1. Hand Impairment in Systemic Sclerosis: Various Manifestations and Currently Available Treatment.

Authors: Amber Young; Rajaie Namas; Carole Dodge; Dinesh Khanna
Journal: Curr Treatm Opt Rheumatol Date: 2016-07-19

2. Systemic sclerosis in 2014: Advances in cohort enrichment shape future of trial design.

Authors: Yannick Allanore; Oliver Distler
Journal: Nat Rev Rheumatol Date: 2015-01-06 Impact factor: 20.543

3. Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis.

Authors: N Del Papa; F Onida; E Zaccara; G Saporiti; W Maglione; E Tagliaferri; R Andracco; D Vincenti; T Montemurro; L Mircoli; C Vitali; A Cortelezzi
Journal: Bone Marrow Transplant Date: 2016-08-22 Impact factor: 5.483

4. TRPV4 ion channel is a novel regulator of dermal myofibroblast differentiation.

Authors: Shweta Sharma; Rishov Goswami; Michael Merth; Jonathan Cohen; Kai Y Lei; David X Zhang; Shaik O Rahaman
Journal: Am J Physiol Cell Physiol Date: 2017-03-01 Impact factor: 4.249

5. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.

Authors: Rajaie Namas; Donald P Tashkin; Daniel E Furst; Holly Wilhalme; Chi-Hong Tseng; Michael D Roth; Suzanne Kafaja; Elizabeth Volkmann; Philip J Clements; Dinesh Khanna
Journal: Arthritis Care Res (Hoboken) Date: 2018-02-09 Impact factor: 4.794

Review 6. Systemic sclerosis: commonly asked questions by rheumatologists.

Authors: Amber Young; Dinesh Khanna
Journal: J Clin Rheumatol Date: 2015-04 Impact factor: 3.517

Review 7. Management of connective tissue diseases associated interstitial lung disease: a review of the published literature.

Authors: Beth Wallace; Dharshan Vummidi; Dinesh Khanna
Journal: Curr Opin Rheumatol Date: 2016-05 Impact factor: 5.006

8. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.

Authors: Dinesh Khanna; Veronica J Berrocal; Edward H Giannini; James R Seibold; Peter A Merkel; Maureen D Mayes; Murray Baron; Philip J Clements; Virginia Steen; Shervin Assassi; Elena Schiopu; Kristine Phillips; Robert W Simms; Yannick Allanore; Christopher P Denton; Oliver Distler; Sindhu R Johnson; Marco Matucci-Cerinic; Janet E Pope; Susanna M Proudman; Jeffrey Siegel; Weng Kee Wong; Athol U Wells; Daniel E Furst
Journal: Arthritis Care Res (Hoboken) Date: 2016-02 Impact factor: 4.794

9. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.

10. [Expression of pituitary tumor-transforming gene-1 and its pathogenic role in systemic sclerosis].

Authors: Anqiao Yang; Yan Huang; Yuting Zhang; Kai Yang; Jiucun Wang; Qingmei Liu
Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2020-11-30